Post-menopausal Women Osteoporosis(Phase III)
Post-menopausal Women Osteoporosis(Phase III)
The purpose of this study is to evaluate the efficacy and the safety of Risedronate,
 cholecalciferol combination tablet in patients with Osteoporosis
The purpose of this study is to evaluate the efficacy and the safety of Monthly Risedronate
 with cholecalciferol on 25 Hydroxyvitamin D level and bone markers patients with
 osteoporosis.
Inclusion Criteria:

 1. women osteoporosis

 2. patients with a diagnosis of Postmenopausal over 6 Months if they had a bone mineral
 density T-score of < -2.5 at the mean lumbar spine (L1-4), femoral neck, or total, or
 a T-score of < -1.0 with radiologic evidence of at least one vertebral fracture.
 Menopause was defined as no natural menses for at least 1 year and a serum FSH level >
 40 IU/L, with a reported hysterectomy

 3. low levels of 25(OH)D > 9 ng/mL

 4. patients who give written consent of agreement to voluntarily participate in the
 clinical study

 5. patients who can read and understand written instructions

 Exclusion Criteria:

 1. patients who had contraindications to oral bisphosphonates, such as esophageal
 strictures

 2. ALT, AST ≥ 2×UNL and Serum Creatinine ≥ 1.5×UNL

 3. low levels of 25(OH)D (less than 9 ng/mL).

 4. Previous use of oral bisphosphonates and vitamin D were allowed, but a washout period
 was needed, depending on the duration of treatment. Two-year washout periods were
 needed for bisphosphonate users and 3-6-month periods were required for vitamin D
 users of > 200 IU.

 5. drug administration after diagnosing as alcoholic or psychical disease

 6. patients whom the investigators judge as improper to participate in this clinical
 trial 7)13.patients who have experience to participate in other clinical trial within
 30 days prior to study participation